drugset / Trial / NCT00963664

Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma

NCT00963664

Phase 2 Withdrawn 250 enrolled NeoPlas Innovation
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine whether an outpatient combination of lovastatin and low-to-moderate dose interferon is effective in the treatment of patients with malignant melanoma.

Timeline

Start
2009-12
Primary completion
2016-12
Completion
2016-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Lovastatin Small molecule 1.5 mg/kg Oral
Subject interferon alfa-2b Protein / enzyme biologic 100000 iu/kg Subcutaneous

Indications